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Abstract
Humanin (HN), a 24-residue peptide, was identified as a novel neuroprotective factor and shows anti-cell death activity
against a wide spectrum of Alzheimer’s disease (AD)-related cytotoxicities, including exposure to amyloid beta (Abeta), in
vitro. We previously demonstrated that the injection of S14G-HN, a highly potent HN derivative, into brain ameliorated
memory loss in an Abeta-injection mouse model. To fully understand HN’s functions under AD-associated pathological
conditions, we examined the effect of S14G-HN on triple transgenic mice harboring APPswe, tauP310L, and PS-1M146V that
show the age-dependent development of multiple pathologies relating to AD. After 3 months of intranasal treatment,
behavioral analyses showed that S14G-HN ameliorated cognitive impairment in male mice. Moreover, ELISA and
immunohistochemical analyses showed that Abeta levels in brains were markedly lower in S14G-HN-treated male and
female mice than in vehicle control mice. We also found the expression level of neprilysin, an Abeta degrading enzyme, in
the outer molecular layer of hippocampal formation was increased in S14G-HN-treated mouse brains. NEP activity was also
elevated by S14G-HN treatment in vitro. These findings suggest that decreased Abeta level in these mice is at least partly
attributed to S14G-HN-induced increase of neprilysin level. Although HN was identified as an anti-neuronal death factor,
these results indicate that HN may also have a therapeutic effect on amyloid accumulation in AD.
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Introduction
Humanin (HN) is a multi-functional 24-residue peptide (amino
acid sequence: MAPRGFSCLLLLTSEIDLPVKRRA) whose
cDNA was isolated from an Alzheimer’s disease (AD) patient’s
occipital lobe of brain, a region that remains generally intact in
many AD cases [1] (reviews in [2,3,4]). HN suppresses the
neuronal death caused by all AD-related insults so far tested in vitro
including the key cytotoxic molecule in AD, amyloid beta (Abeta)
1-42 [1,5,6]. HN suppressed cell death caused by Abeta toxicity
not only in primary neurons but also in cerebrovascular smooth
muscle cells, a model of amyloid angiopathy [7]. HN is also
effective against cell death caused by non-AD-related insults under
different experimental settings, such as serum depriviation, prion
peptide118-135, IGFBP3 (insulin-like growth factor binding
protein 3), staurosporine etc. [8,9,10,11]. However, HN is not
effective against some insults such as etoposide, suggesting that HN
is not a general anti-apoptotic agent.
It has been hypothesized that HN stimulates its receptor(s) and
activates signaling cascade(s) to exert its effects [2,4]. Upon HN
stimulation, G protein coupled receptors, formyl peptide receptor-
like (FPRL) 1 and FPRL2 [12,13], induce increase of Ca
2+ flux
and activation of extracellular signal-regulated kinase (ERK),
while a receptor complex consisting of gp130, CNTFR, and
WSX-1 [14] induces activation of a transcription factor, signal
transducer and activator of transcription 3 (STAT3). In addition,
three receptor-independent mechanisms have been proposed. (I)
Intracellular HN bound to pro-apoptotic Bcl-2 family members,
Bax, BimEL, and tBid, and blocked cytochrome c release from
mitochondria, leading to inhibition of apoptosis [11,15,16]. (II)
HN increased cellular ATP levels in human lymphocytes and a
muscular cell line [8,17,18,19,20]. (III) Extracellularly added HN
was detected in the cells and suppressed apoptosis induced by
IGFBP3 [10].
Through structure-function analyses, we found that a substitu-
tion of Gly for 14th Ser (S14G-HN) increased potency 1000-fold
[1]. S14G-HN ameliorated amnesia caused by muscarinic
receptor antagonists [21,22,23] and Abeta in mice [23,24].
S14G-HN also ameliorated symptoms and/or pathology in rodent
stroke model [25,26] and diabetes models [27,28]. These findings
suggest the potential of HN for therapeutic application in AD and
other diseases.
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16259To evaluate the effect of HN derivatives in vivo, Abeta injection
model was used in the previous studies [23,29,30]. In this model,
Abeta administration induces amnesia in rodents, decreases the
number of cholinergic neurons [31], and reduces choline
acetyltransferase activity [32,33,34,35] Although the Abeta
injection model is a simple and convenient model, the transgenic
mouse model has some advantages, for instance production of
multiple Abeta species through physiological process and amyloid
plaque formation. The triple transgenic mice harboring APPswe,
tauP310L, and PS-1M146V (3xTg-AD) [36] have the advantage of
the age-dependent development of multiple pathological events
relating to AD. In these mice, memory impairment was observed
by Morris water maze test at 9 months of age. Soluble Abeta was
observed from 9 months of age and plaques from 14 months by
immunohistochemical analyses. They also develop tau pathology:
total tau protein increased age-dependently, correlating with a
decrease of soluble tau and an increase of insoluble tau [37].
Therefore, they are beneficial to examine the effect of therapeutic
candidates on pathological changes under the complex physiolog-
ical conditions.
We previously demonstrated that Abeta-induced amnesia was
suppressed by intracerebroventricular injection of S14G-HN [23].
To fully understand HN’s functions on complex AD-relevant
pathology, in this study, we used triple transgenic mouse model.
We found that S14G-HN ameliorated cognitive function of 3xTg-
AD mice and reduced amyloid burden accompanied by an
increase in neprilysin level in the hippocampal region.
Materials and Methods
Animals and treatment
Triple transgenic (3xTg-AD) mice were housed under 12 hour
light, 12 hour dark cycles with food and water provided ad
libitum. Male and female 3xTg-AD mice (n=9 in each group) at
the age of 13 months (13.260.6) were treated intranasally with
10 nmol of S14G-HN (Peptide Institute, Japan) or vehicle (water)
for 3 and half months. Treatment was carried out 5 days a week
(weekdays) for the initial 2.5 months and everyday during the last 1
month. After 3 months of treatment, 7 male and 9 female mice in
the vehicle control group and 9 male and 7 female mice in the
S14G-HN treatment group were subjected to behavioral analyses.
After 1 week of the last behavioral test (24 hours after the last
treatment), mice at 17 months of age were sacrificed by cervical
dislocation as described in Planel et al. [38]. Half hemispheres of
the brains were rapidly frozen for immunoblot and ELISA
analyses and the other half hemispheres were fixed with 4%
paraformaldehyde for histological analyses. To examine the
delivery of S14G-HN to brain, 3xTg-AD mice (female, 20 months
of age) were treated intranasally with 10 nmol of S14G-HN or
vehicle (water). After 1 hour of administration, mice were
sacrificed and brains were fixed with 4% paraformaldehyde for
histological analyses. All experimental procedures were approved
by the Georgetown University Animal Care and Use Committee
(Protocol #07-016).
Open Field test
The open field test was performed as described in Takahashi
et al. [39]. The apparatus was a rectangle container (45 cm635 cm
and 15 cm height). The peripheral area was designated within
10 cm from the walls. Each mouse was placed at a corner and the
activities were recorded for 5 min. Mouse behaviors (walking
distance, speed, and duration spent in peripheral area) were
analyzed by TopScan software (Cleaver System Inc., VA).
Novel object recognition task
The novel object was performed as described in Nagai et al.
[40]. The apparatus was a rodent cage (43 cm 627 cm 622 cm).
Two identical objects were presented to a mouse in the apparatus
for 5 min and the time spent exploring the objects was recorded.
After 30 min, the mouse was returned to the arena where one
object was replaced with a novel object and the mouse was allowed
to explore for 5 min. The exploring time for each object was
recorded. All behavior was recorded and analyzed by TopScan
software. The object discrimination of normal rats is greatest in the
initial two minutes [41], so we focused on the first two minutes of
exploring time to determine cognitive function of mice and
calculated Discrimination ratio (DR) as described in Winters et al.
[42]: DR = (N-F)/T, where N is time spent exploring the novel
object, F is time spent exploring the familiar object, and T is total
time spent exploring two objects.
Morris water maze
The Morris water maze was performed as described by
Matsuoka et al. [43]. The circular pool (diameter 150 cm, height
30 cm, painted white) was filled with water (2261.0uC). A
circular, white escape platform (diameter 10 cm) was submerged
1 cm below the water surface, 30 cm off the rim of the pool.
Training trials, 120 sec each, were performed twice a day during 5
consecutive days. The platform location and the animal’s starting
point were held constant within each pair of daily tests, but the
location of the platform and the animal’s starting point were
rotated by 90u every day. The mice were allowed to stay on the
platform for 20 sec before and after each trial. On the fifth day, a
probe test was preformed after the second daily trial. The platform
was removed from the maze and swimming behavior was recorded
for 2 min. Mice were then subjected to a visible platform test. A
black escape platform was placed at 1cm above the water in the
same place in training trials in the 5th day. Each mouse was
released into the water and the time taken to find the platform was
recorded (maximum 60 seconds). Animals that did not climb on
the platform during this test were excluded from the statistical
analysis. All behavior was recorded and analyzed by TopScan
software.
Abeta ELISA
The method is described in Hirata-Fukae et al. [37]. Briefly,
brains were homogenized in buffer (50 mM Tris-HCl, pH 7.4,
1 mM EDTA) with protease inhibitors (Halt Protease Inhibitor
Cocktail, Pierce) and phosphatase inhibitors (Phosphatase inhib-
itor Cocktail set, Calbiochem). Soluble Abeta was extracted with
0.4% diethylamine as described in Schmidt et al. [44] and
subjected to ELISA as described in Horikoshi et al. [45].
Immunohistochemical analysis
Immunohistochemical staining was described in Hirata-Fukae
et al. [37]. Briefly, 30 mm sagittal sections were subjected to
immunostaining using anti-HN (P04) [46], anti-Abeta antibody
(82E1, IBL), anti-phosphorylated tau (Ser202) (AT8, Pierce), anti-
phosphorylated tau (Thr231) (AT180, Pierce), or anti-insulin
degrading enzyme (IDE) (Abcam) and biotin-conjugated second-
ary antibody followed by visualization with avidin-fluorescein for
HN or ABC method (Vector Laboratories) for others. Immuno-
staining with anti-neprilysin (NEP) antibody (clone 56C6, Abcam)
and anti-synaptophysin (SVP-38, Sigma) were performed as
described in Iwata et al. [47] and Tomiyama et al. [48],
respectively. Immunostaining with anti-phosphoTyr705-STAT3
antibody (Cell Signaling) was performed according to the
Humanin Reduces Amyloid Burden
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ary antibody (Pierce). For quantitative analysis, staining intensity
was measured with ImageJ.
Immunoblot analysis
Brain homogenate was subjected to SDS-PAGE (Nu-PAGE,
Invitrogen), followed by transfer to polyvinilydendifluoride mem-
brane (Millipore). Membranes were blocked with 5% BSA in TBS-
T (20 mM Tris-HCl pH 7.6, 136 mM NaCl, and 0.1% Tween
20), and incubated with primary antibody and secondary antibody
(horseradish peroxidase conjugated anti-mouse or rabbit IgG) in
2% BSA in TBS-T, followed by detection with enhanced
chemiluminescence reagent (Thermo Scientific). Primary antibod-
ies were anti-APP (IBL), anti-sAPPalpha (IBL), anti-phosphorylat-
ed-tau (Ser202) (AT8, Pierce), anti-phosphorylated tau (Thr231)
(AT180, Pierce), anti-total tau (Tau46, Sigma), and anti-beta-actin
(Sigma). Anti-phosphoTyr705-STAT3, anti-total STAT3, anti-
phosphoSer473-Akt, anti-phosphoThr308-Akt, and anti-total Akt
were from Cell Signaling.
NEP activity assay
F11 neuronal cells were cultured in Ham’s F12 medium
supplemented with 18% fetal bovine serum, penicillin/streptomy-
cin (Gibco). Cells were treated with 500 nM S14G-HN or vehicle
(water) for 2 hours. Cell lysate was subjected to NEP activity assay
as described in Hemming et al. [49]. Briefly, cell lysate was mixed
with 1 mM captopril (MP Biomedicals) and incubated with
substrate, 3-dansyl-D-Ala-Gly-p-(nitro)-Phe-Gly (DAGNPG; Ba-
chem) in the presence or absence of 10 mM phosphoramidon
(American peptide). Reaction was stopped by heating. After
clarifying reaction mix by centrifugation, fluorescent intensity was
measured by a plate reader (excitation 340, emission 535, TECAN
ULTRA).
Data analysis
Data was statistically analyzed by t-test, Mann-Whitney U test,
(SPSS) or non-parametric ANOVA (Kruskal-Wallis test) followed
by Dunn’s post-hoc test (Prism).
Results
S14G-HN does not affect locomotor activity of 3xTg-AD
mice
Intranasal administration is a method for delivery of therapeutic
agents directly and efficiently to the brain [50]. We treated 3xTg-
AD mice with S14G-HN intranasally, and performed immuno-
histological staining with anti-HN antibody (P04) [46]. Based on
the study on IGF-I [51] we focused on olfactory tract area, and
found positive immunostaining in olfactory tubercle region (Fig. 1).
This suggests that S14G-HN is transported into brain through a
pathway associated with the peripheral olfactory system as
described in [51].
To examine the effect of HN, we designed a 3-month treatment
study using male and female 3xTg-AD mice (n=9 in each group)
at the early plaque-bearing stage. Since the progression of Abeta
pathology in our colony is slower than that in the original colony
[37], we started the treatment of mice at the age of 13 months
(13.260.6). S14G-HN showed complete neuroprotective activity
at 1nM of concentration in vitro [1,6]. To achieve approximately
1nM of concentration in CNS, we chose a dose of S14G-HN at
10 nmol/day, based on the finding that intranasal administration
of 5 nmol [
125I]-IGF-I resulted in 0.32–1.44 nM of concentration
in CNS region [51]. We treated male and female 3xTg-AD mice
intranasally for three months with 10 nmol S14G-HN. After three
months of treatment, we performed behavioral tests. In the Open
Field test (Fig. 2A–C), no significant difference was observed
between the vehicle and S14G-HN treated mice in total moving
distance (Fig.2A), walking speed (Fig.2B), and time spent in
peripheral area (Fig.2C). These results indicate that S14G-HN did
not affect anxiety-induced locomotor activity and exploratory
behaviors. In the Novel object recognition test (Fig. 2D), S14G-
HN treated mice showed a trend toward improved recognition,
though not reaching statistical significance.
S14G-HN ameliorates deficit in spatial learning and
memory in 3xTg-AD mice
In the Morris water maze test, training trials (2 min each) were
performed twice a day for 5 days. To assess flexible learning
ability, the position of the platform was rotated everyday. The
parameter of learning flexibility was analyzed by looking at the
block of first trials performed each day (Fig. 3A). S14G-HN treated
male mice showed a trend of shorter latency than control on the
second day. In female mice, no significant difference was observed
between S14G-HN-treated and control mice. On the fifth day, the
probe test was performed after the second daily trial. Time spent
in each quadrant of pool was significantly different in S14G-HN
treated male mice but not in vehicle control male mice by non-
parametric ANOVA (Fig. 3B). Post-hoc test on values of S14G-
HN-treated male mice detected a significant difference between
platform quadrant and opposite quadrant (p,0.05). Consistently,
time spent in the area within 60 cm from the platform location
was significantly longer for S14G-HN treated male mice than for
vehicle control mice (Fig. 3C). These results show that S14G-HN-
treated male mice stayed close to the platform location longer than
vehicle control mice, suggesting better cognitive and memory
function of S14G-HN-treated mice than control. We also
measured the duration that mice spent in the platform location
(Fig. 3D). In the first 30 sec of probe test, S14G-HN-treated male
mice stayed in the platform area significantly longer than control
male mice. S14G-HN treated female mice showed a trend similar
to the male mice, though the difference was not significant
(Fig. 3B–D). Swimming speeds of S14G-HN treated and control
mice were virtually the same in probe test (data not shown),
indicating that locomotion activity was not affected by S14G-HN.
Abeta level was reduced in brain of S14G-HN-treated
3xTg-AD mice
Since Abeta pathology may correlate to cognitive function, we
examined the levels of Abeta in brain from 3xTg-AD mice treated
with S14G-HN or vehicle by ELISA. Total Abeta40 in vehicle
control, both male and female (Fig. 4A grey columns), showed
levels consistent with the expected age-dependent increase of
Abeta in naı ¨ve mice reported in Hirata-Fukae et al. (2008) (Fig. 4A
dotted lines). Compared with vehicle control, the levels of Abeta40
in S14G-HN mice (Fig. 4A black columns) were markedly low in
both male and female mice, though statistical significance was
detected only in females. A similar trend was observed in soluble
Abeta40 levels in both genders, though the difference was not
significant (data not shown). We also performed ELISA to detect
total Abeta42. Since Abeta42 level is still low at this age of 3xTg-
AD mice, many samples resulted in undetectable level: 2 out of 7
vehicle male, 6 out of 9 S14G-HN-treated male, none of vehicle
female, and 5 out of 7 S14G-HN-treated female mice showed
undetectable level of Abeta42. Given zero as a value of these
undetectable samples, Abeta42 levels (mean6SE, pmol/g tissue)
were vehicle male (n=7); 6.563.9, S14G-HN male (n=9);
3.862.1, vehicle female (n=9); 46.0620.4, S14G-HN female
Humanin Reduces Amyloid Burden
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and female, respectively. These results indicate that Abeta42 level
had a trend similar to that of Abeta40 (Fig. 4), i.e. decreased level
of Abeta in S14G-HN-treated mice.
To confirm the finding obtained by ELISA, we examined the
amount of amyloid plaques by immunohistochemical analysis
using anti-Abeta antibody 82E1, which specifically recognizes
Abeta but not APP. Representative results are shown in Fig. 4B–
G. We stained six sections per mouse at 150 mm intervals and
evaluated the number of plaques (count), total area, and integrated
density of staining in subiculum region of each section (summa-
rized in Table 1). Both total area and integrated density were
significantly lower in S14G-HN-treated 3xTg-AD female mice
than the vehicle control. The similar trend was observed in male
mice as in female. As observed in the results of ELISA (Fig. 4A), no
statistical significance was detected in males because of large
individual variations (data not shown). Combined with the results
of ELISA, these results indicate that S14G-HN suppresses the age-
related increase of plaque burden in 3xTg-AD mouse brains.
APP production and processing was not affected by
S14G-HN
To understand how S14G-HN suppresses Abeta accumula-
tion, we next examined the levels of full-length APP and
sAPPalpha, a cleaved product of alpha-secretase. We performed
immunoblot analysis of brain homogenate using antibodies that
specifically recognize C-terminal regions of APP and sAPPalpha,
respectively (Fig. 5). Quantitative analysis showed no significant
difference in levels of full-length APP and sAPPalpha between
S14G-HN and vehicle treated mice (number of animals; vehicle
male=7, female=9, S14G-HN male=9, female=7): relative
intensity of full-length APP and sAPPalpha bands in S14G-HN-
treated brain homogenate (indicated as percentage of corre-
sponding vehicle control, mean6SD) was 98617 (male),
106615 (female) and 81615 (male), 98616 (female), respective-
ly. In addition, we detected no difference in sAPPbeta level
between S14G-HN and vehicle control (data not shown). These
results suggest that S14G-HN altered neither APP production
nor processing by secretases.
Figure 1. Delivery of S14G-HN to brain by intranasal administration. 3xTg-AD mice (13 month-old) were intranasally administrated with
S14G-HN (B) or vehicle (A), and sacrificed after 1 hour of administration. Brains were fixed with 4% paraformaldehyde and 30 mm sagittal sections of
brains were subjected to immunostaining using anti-HN antibody (P04) and biotin-conjugated secondary antibody followed by visualization with
avidin-fluorescein. ACB, Nucleus accumbens; AON, Anterior olfactory nucleus; NBD, Diagnal band nucleus; OT, Olfactory tubercle; SI, Substantia
innominata. Bar=500 mm.
doi:10.1371/journal.pone.0016259.g001
Figure 2. The effect of S14G-HN on locomotor activity of 3xTg-AD mice. Male and female 3xTg-AD mice were subjected to behavioral
analyses, Open field test (A–C) and Novel object recognition task (D), after 3 months intranasal administration of S14G-HN or vehicle. In Open field
test, walking distance (A), walking speed (B) and duration stayed in the peripheral region (C) were measured. No significant difference was observed
between S14G-HN and vehicle-treated mice in both genders. In Novel object recognition task, time of sniffing behavior to two objects was measured.
In the first trial, no preference was observed in sniffing time of two objects (data not shown). The discrimination ratio in the second trial is shown (D).
Bars indicate median, and p= indicates p value of Mann-Whitney U test. Number of animals are male vehicle control: n=7, S14G-HN: n=9, female
vehicle control: n=8, S14G-HN: n=7.
doi:10.1371/journal.pone.0016259.g002
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We next examined expression of Abeta-degrading endopepti-
dase, neprilysin (NEP), in S14G-HN and vehicle treated mouse
brains (Fig. 6A–F). NEP level is reduced in the specific regions of
brain, such as hippocampus, with AD and aging [47,52]. In the
dentate gyrus, lower NEP expression was observed in the outer
molecular layer but not in the middle molecular layer by aging
[47]. We performed immunohistochemical staining of brain
sections using anti-NEP antibody (Fig. 6A–F). To evaluate the
staining results quantitatively, we measured staining intensity of
the middle and outer molecular layers. The raw values of
measured staining intensity of outer molecular layer of vehicle
and S14G-HN-treated mice (arbitrary units, mean6SD) were
38.2612.0 (male), 37.566.4 (female) and 40.567.0 (male),
38.664.8 (female), respectively. To normalize the variation in
overall staining intensity of sections, the ratio of staining intensity
(outer layer/middle layer) was calculated. The ratio was
significantly higher in S14G-HN-treated mice than control in
both male (n=3) and female (n=4) (Fig. 6G). These results suggest
that S14G-HN sustains or increases NEP expression in specific
brain regions. We also performed immunohistological staining of
brain sections with anti-insulin degrading enzyme (IDE), another
major Abeta-degrading enzyme [53,54] (Fig. 6H–K). Since levels
of IDE in hippocampal CA2 and CA3 regions but not CA1 region
are reduced in AD cases [55], we measured staining intensity of
IDE in these brains. No significant difference was detected in levels
of IDE in both CA1 and CA3 regions between S14G-HN and
vehicle treated mice: relative intensities of IDE in S14G-HN-
treated brain homogenate (indicated as percentage of correspond-
ing vehicle control, mean6SD, n=3) were 103.567.0 (male),
95.0612.3 (female) in CA1 region and 91.466.9 (male),
104.463.1 (female) in CA3 region.
We further examined the effect of S14G-HN on NEP activity
using neuronal F11 cell line. After 2 hours of treatment of cells
with S14G-HN, we measured NEP activity with Dansyl-D-Ala-
Gly-4-nitro-Phe-Gly-OH (DAGPG) in the presence or absence of
phosphoramidon, a NEP inhibitor (Fig. 6L). Specific NEP activity
in cells treated with S14G-HN was significantly increased,
suggesting that S14G-HN can modulate NEP activity in neurons.
S14G-HN did not affect tau phosphorylation in 3xTg-AD
mice
A major characteristic of 3xTg-AD mice is age-dependent
progression of tau pathology. We thus examined the effect of
S14G-HN on tau pathology. Phosphorylation of tau protein was
assessed by immunoblot using phosphorylation site-specific
antibodies (AT8, AT180, and AT270 for Ser208, Thr231, and
Thr181, respectively). Total tau was assessed by tau46 antibody.
The level of total tau (normalized by actin) was not changed by
S14G-HN (Fig. 7A,B). The relative intensity of bands in S14G-
HN-treated mouse brain homogenate (percentage of correspond-
ing vehicle control, mean6SD) was 100621 (male) and 112617
(female). The ratio of phosphorylated tau (Ser202) to total tau was
not different between S14G-HN treated and control mice: the
value of S14G-HN calculated as percentage of corresponding
vehicle control (mean6SD) was 101639 (male) and 95623
(female). No significant difference between S14G-HN treated and
control mice was detected in phosphorylation of Thr231 (Fig. 7B)
Figure 3. The effect of S14G-HN on spatial memory in 3xTg-AD mice. Male and female 3xTg-AD mice were subjected to Morris Water Maze
after 3 months of intranasal administration with S14G-HN or vehicle. A. Training sessions. Training trials (120 sec each) were performed twice a day
for 5 days. Time spent to find platform in first trial in each day is shown as mean6SEM. B–D. Probe test. Time spent in each quadrant is shown as
mean6SEM (B). Mice which did not find the visual platform were considered abnormal mice and data of these mice was excluded from analysis
(vehicle male=3, female=2, S14G-HN male=1, female=2). P values of non-parametric ANOVA test (Kruskal-Wallis test) are shown. Time spent within
60 cm from the platform region during first 60 seconds of probe test is shown as mean6SEM (C). Time spent within platform area during first 30
seconds of probe test is shown as mean6SEM (D). In C and D, p= indicates p values of Mann-Whitney U test.
doi:10.1371/journal.pone.0016259.g003
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observed between vehicle and S14G-HN treated mouse brains by
immunohistochemical analysis using anti-phosphorylated tau
antibody AT8 (Fig. 7C, D) and AT180 (Fig.7E, F). Thus, S14G-
HN showed no effect on tau pathology at least at the early plaque-
bearing stage.
Neuroprotective effect of S14G-HN in 3xTg-AD mice
To evaluate the effect of S14G-HN on neurodegeneration in
3xTg-AD mice, we examined synaptic density by detecting a
synaptic marker synaptophysin (Fig. 8A–D). Compared with the
vehicle control, the levels of synaptophysin in hippocampal CA3
region of S14G-HN mice were significantly higher in both male
and female mice (Fig. 8E); average of arbitrary units (mean6SD)
were 44.863.9 (vehicle), 53.860.7 (S14G-HN) in male mice and
23.761.0 (vehicle), 26.260.8 (S14G-HN) in female mice. There
results suggest a protective effect of S14G-HN against synaptic
degeneration.
Since STAT3 and Akt have been implicated in neuroprotective
activity of HN [26,56], we examined activation of STAT3 and Akt
in 3xTg-AD mouse brains by immunoblot analysis of total brain
homogenate (Fig. 9A,C,E). The ratio of phosphorylated STAT3
(Tyr705) to total STAT3 showed a weak trend toward increase in
STAT3 activity in S14G-HN-treated mice compared with control
mice, but no significant difference was detected (Fig. 9B). In the
immunohistochemical analysis using anti-phospho-STAT3 anti-
body, both overall staining (Fig. 9G–J) and quantitative measure-
ment of staining intensity in CA3 region (Fig. 9L) showed no
significant difference between S14G-HN-treated and control
mouse brains. As for Akt activation, the phosphorylation level of
Ser473 showed no difference by the treatment (Fig. 9C,D),
whereas phosphorylation of Thr308 was significantly higher in
S14G-HN-trated mouse brains than control (Fig. 9E,F). These
results can be interpreted that S14G-HN might induce transient
activation of STAT3 and Akt signaling cascades but may not cause
continuous activation of signaling molecules in vivo.
Figure 4. Brain Abeta level was sustained in S14G-HN-treated 3xTg-AD mice. After behavioral tests, mice were sacrificed at 17 months of
age. Abeta was extracted from brain homogenates using formic acid. A. Amount of human Abeta40 was measured by ELISA and shown as
mean6SEM. P values of Student t-test are shown. Number of animals were vehicle male=7, female=9, S14G-HN male=9, female=7. Lower level of
Abeta was detected in S14G-HN treated mice (black columns). Statistical significance was observed in female but not male compared with vehicle
treated mice (dark grey columns). Dotted line plots show Abeta40 levels of naı ¨ve 3xTg-AD mice at the indicated age [37]. B–G. Immunohistochemical
analysis of amyloid plaques. Brains were fixed with 4% paraformaldehyde and 30 mm sagittal sections were subjected to immunostaining using anti-
Abeta antibody (82E1) and biotin-conjugated secondary antibody followed by visualization with ABC method. B, D, F. vehicle-treated female mice,
C, E, G. S14G-HN-treated female mice. F, G. magnified view of subculum regions in C and E, respectively. Bar =500 mm in B-E, =100 mmi nF ,G .
doi:10.1371/journal.pone.0016259.g004
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This study demonstrated that 3-month treatment of a highly
potent HN derivative S14G-HN suppressed the deterioration of
cognitive and memory functions (Fig. 3), synaptic degeneration
(Fig. 8) and the increase in amyloid burden (Fig. 4, Table 1) in
3xTg-AD mice. Since Abeta, particularly soluble Abeta oligomers,
have been demonstrated to induce synaptic dysfunction and
memory impairment [57], the improved cognitive function by
S14G-HN may be at least partly attributed to the reduced Abeta
level in S14G-HN-treated mouse brains. The pro-cholinergic
effect of HN might also contribute to the S14G-HN-induced
cognitive benefit, since HN ameliorates amnesia caused by
muscarinic receptor antagonists [21,22,23]. Although reduced
Abeta level in brains of S14G-HN-treated mice was confirmed by
both ELISA and immunohistological analysis (Fig. 4, Table 1), no
significant change was observed in levels of full-length APP,
sAPPalpha, and sAPPbeta in whole brain homogenates of these
mice (Fig. 5). This indicates that S14G-HN does not modulate
APP production or secretase activities in vivo. On the other hand,
we observed higher levels of NEP in the outer molecular layer of
hippocampal formation in S14G-HN-treated mice than in control
mice (Fig. 6A–G), while IDE levels were not affected by S14G-HN
treatment (Fig. 6H–K). NEP activity was also elevated by S14G-
HN treatment in vitro (Fig. 6L). These observations suggest that the
higher level of NEP in some brain regions contributes to the
reduced Abeta level in brains of S14G-HN-treated mice. The
molecular layer of dentate gyrus comprises the dendrites and
axons arising from the entorhinal cortex and the intrinsic systems
[58], indicating this region is susceptible to Abeta toxicity. In fact,
soluble Abeta interfered with long-term potentiation in CA1 and
dentate gyrus of the hippocampus [59,60] and spine density is
decreased in the outer layer of the dentate gyrus of AD mouse
models [61,62]. Therefore, the reduction of Abeta level in the
molecular layer through increase in local NEP levels may
contribute to S14G-HN-dependent amelioration of memory
impairment in 3xTg-AD mice.
A behavioral test demonstrated that S14G-HN rescued
cognitive function in 3xTg-AD male mice, whereas it showed a
less clear effect in female mice (Fig. 3). The difference in HN’s
effect between genders may be attributed to the difference in the
stage of Abeta pathology, because 3xTg-AD female mice showed
more aggressive Abeta pathology than male mice in the plaque-
bearing stage (Fig. 4) [37]. Namely, S14G-HN can induce high
enough NEP levels to reduce Abeta level for preserving cognitive
function in the early Abeta accumulating stage, while it was not
enough in the advanced plaque-bearing stage.
HN-like molecule was detected in non-CNS organs [17,27,46],
and the level of HN in serum was decreased age-dependently in
human and rodents [27]. Given that the systemic administration of
S14G-HN showed an effect similar to that of intracerebroven-
tricular injection of S14G-HN [22,25], it is hypothesized that HN
circulated in blood stream is transferred into brain by a so far
unidentified mechanism [4], and that serum level of HN correlates
to the level and effectiveness of HN in brain. It is interesting to
note that the NEP level in outer molecular layer is decreased by
aging [47]. Taken together with our finding of NEP levels in outer
molecular layer of hippocampal formation (Fig. 6), age-dependent
decrease in endogenous HN levels associated with low NEP
expression may be linked to increased risk for progression of AD
by aging.
This study showed that both total amount and phosphorylation
status of tau were unaffected by S14G-HN treatment in 3xTg-AD
Table 1. Decreased amyloid burden in S14G-HN-treated
mice.
Count Total Area Average Size IntDen
Vehicle Mean 259.8 74364 165.1 16048999
SD 37.5 14899 19.1 4509234
S14G-HN Mean 208.5 35807 56.6 7610845
SD 54.1 13482 0.02 2787706
% of veh Mean 80.3 48.2 34.3 47.4
SD 20.8 18.1 0.01 17.4
t-test P= 0.176 0.009 0.016 0.024
Brain sections were prepared as described in Fig. 4. Subiculum region of each
section was subjected to quantitative analysis using ImageJ. Number of plaques
(Count), total immunopositive region (Total Area), and integrated density
(IntDen) were measured and Average size of particles (plaques) was calculated
(Total Area/Count). Value of six sections of each animal at 150 mm intervals
were summed. Mean and SD of four female animals per group are shown. The
relative ratio of S14G-HN-treated group to vehicle group is indicated as % of
vehicle. P= indicates P value of t-test.
doi:10.1371/journal.pone.0016259.t001
Figure 5. S14G-HN does not affect APP production and processing. Brain homogenate of 3xTg-AD mice treated with S14G-HN (HNG or H) or
vehicle (veh or V) was subjected to immunoblot analysis using anti-APP C-terminus (A) or anti-sAPPalpha (B) (upper panels) and anti-beta-actin
(lower panels) antibodies.
doi:10.1371/journal.pone.0016259.g005
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3xTg-AD mice, tau pathology becomes apparent between 12 to 15
months of age and staining with PHF1 antibody, a marker of late
stage of tau pathology, is evident at 18 months of age [36]. No
significant gender difference was observed for onset and
progression of tau pathology [37]. The cognitive decline was
reversed by Abeta immunotherapy in young 3xTg-AD mice [63],
indicating that the reduction of soluble Abeta level is sufficient for
the prevention of memory impairment in the early stage of Abeta
pathology. However, in aged 3xTg-AD mice with advanced Abeta
and tau pathologies, reduction of soluble Abeta alone did not
improve the cognitive phenotype, while reduction of both soluble
Abeta and soluble tau ameliorated cognitive deficit [64]. We
performed behavioral tests with these mice at 16 to 17 months of
age, which corresponds to mid-stage of tau pathology. It is thus
possible that progressing tau pathology contributed to cognitive
decline in these mice, and that the lack in the effect of S14G-HN
on tau pathology may be a reason for the lack in significant effect
of S14G-HN on behavioral tests in female mice, which carry
advanced Abeta burden [37]. On the other hand, in the transgenic
mice with human P301S mutant tau, synaptic dysfunction and its
loss were detected prior to the appearance of fibrillary tau,
indicating that soluble tau causes these manifestations [65]. In our
study, S14G-HN-treated female mice showed potentially better
cognitive functions, though not statistically significant, compared
to the vehicle-treated male mice despite of the similar levels of
Abeta in these two groups of animals (Figs. 3 C,D, 4A). If soluble
tau contributes to the cognitive impairment of 3xTg-AD mice at
this pathological stage, S14G-HN might have certain antagonistic
effects on soluble tau-induced cognitive dysfunction in addition to
that induced by Abeta. Alternative interpretation is that systemic
effects of S14G-HN may contribute to the improvement of
cognitive functions. Halagappa et al. [66] showed that intermittent
fasting improved cognitive functions of 3xTg-AD mice without
reducing phospho-tau levels and proposed that dietary manipu-
lation increases the resistance of neurons to the adverse effects of
tau pathology. HN injected in brains of rats modulates glucose
metabolism by improving hepatic and peripheral insulin sensitivity
[27]. It is, thus, possible that S14G-HN might have similar
systemic effects as dietary manipulation. Moreover, several studies
suggest that insulin resistance may increase the risk of AD through
multiple mechanisms including increases in Abeta and inflamma-
tion [67,68]. Therefore, an action mechanism of HN that
ameliorates insulin resistance and hyperglycemia [27] may
contribute to beneficial effects of HN on AD-related pathologies.
Previous studies demonstrated that several signaling molecules
are involved in HN’s activities in vivo and in vitro. STAT3 and
related kinase(s) are involved in the anti-neuronal death activities
of HN in vitro [14,56] and activated in vivo [27,69]. In addition to
anti-cell death effects, these kinases are also involved in the
antagonizing effect of HN against amnesia caused by muscarinic
receptor blockade in vivo [23]. STAT3 contributes to the effect of
Figure 6. Effect of S14G-HN on NEP and IDE. A–F, H–K. Brain sections were subjected to immunostaining using anti-NEP antibody (A–F)o r
anti-IDE (H–K) and biotin-conjugated secondary antibody followed by visualization with ABC method. A, B, H, I. vehicle-treated mice, D, E, J, K.
S14G-HN-treated mice. C, F. magnified view of boxed region in A and D, respectively. Bars =500 mm. mml: middle molecular layer, oml: outer
molecular layer. G. Result of quantitative analysis on NEP is shown as mean6SD. P= indicates p value of t-test. L. F11 cells were treated with S14G-
HN or vehicle for 2 hours. Specific NEP activity in cell lysate was calculated by subtracting activity cleaving DAGNPG substrate in the presence of NEP
inhibitor, phosphoramidon, from the total activity and shown in mean6SD (n=4) of relative fluorescent units (RFU)/mg protein.
doi:10.1371/journal.pone.0016259.g006
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pathways are implicated in neuroprotection of HN against
cerebral ischemia/reperfusion injury in vivo [25,26]. p38 and
STAT3 are involved in apoptosis induced by trophic factor
withdrawal in human leukemia cell line and pancreatic beta-cell
line, respectively [28,70]. In this study, we did not detect
significant changes in phosphorylation of Tyr705 in STAT3 and
Ser473 in Akt, while phosphorylation of Thr308 in Akt was
significantly increased in S14G-HN-treaed 3xTg-AD mouse
brains compared with control (Fig. 9). Since full activation of
Akt requires dual phosphorylation on both Ser473 and Thr308
[71], these findings are insufficient to prove the involvement of
PI3K-Akt pathway in HN-mediated neuroprotection in 3xTg-AD
mice. Considering that PDK1 (phosphoinositide-dependent pro-
tein kinase-1), a major kinase for phosphorylation of Thr308 in
Akt, plays an indispensable role in Akt-independent cell survival
signaling pathway induced by brain-derived neurotrophic factor
[72], it is speculated that S14G-HN may activate the PDK1-
mediated neuroprotective mechanism. In contrast, lack of
increased STAT3 activation in S14G-HN-treated mouse brains
(Fig. 9) is inconsistent with previous findings that STAT3 has an
essential role in the neuroprotecitve effect of HN [56]. A possible
reason for this discrepancy is that S14G-HN-induced activation of
STAT3 (and Akt) was transient and thus we could not detect them,
since we sacrificed mice 24 hours after the last treatment.
In this study, we observed that S14G-HN increased region-
specific NEP levels (Fig. 6). NEP expression is regulated by APP C-
terminal fragment, AICD [73]. Since S14G-HN did not change
APP production and processing (Fig. 5), S14G-HN may not affect
this mechanism, unless region/cell-specific effect exists. Rather,
HN may evoke other unidentified mechanisms to modulate NEP
expression. In fact, since NEP levels are substantially reduced but
not diminished in presenilin-deficient mice, it is hypothesized that
there is an AICD-independent mechanism [73]. On the other
hand, we also observed that S14G-HN increased NEP activity in
vitro (Fig. 6L). NEP activity in primary neurons was unaffected by
treatment with MAPK inhibitor as well as stimulation with insulin
and IL-6, which are related to Akt and STAT3 pathways,
respectively [74], suggesting that these signaling pathways do not
play essential roles in modulation of NEP activity. Somatostatin is
a NEP modulator and enhances NEP activity via activation of
somatostatin receptor coupled with G-protein, Gi/o [74]. Since
HN receptor FPRL1 is coupled with Gi/o, downstream signaling
cascade(s) of this receptor may play an important role in NEP
regulation. Further detailed studies will be necessary to understand
Figure 7. Effect of S14G-HN on tau phosphorylation. A, B. Brain
homogenate of 3xTg-AD mice treated with S14G-HN (H) or vehicle (V)
was subjected to immunoblot analysis using anti-phosphorylated tau
(Ser202) (AT8) (upper panel in A), anti-phosphorylated tau (Thr231)
(AT180) (upper panel in B), anti-total tau (tau46) (middle panels) and
anti-beta-actin (lower panels) antibodies. C–F. Brain sections were
subjected to immunostaining using anti-phosphorylated tau (Ser202)
(AT8) antibody (C, D) or anti-phosphorylated tau (Thr231) (AT180)
antibody (E, F) and biotin-conjugated secondary antibody followed by
visualization with ABC method. Representative images of hippocampal
CA1 region of vehicle (C, E) and S14G-HN (D, F) treated mouse sections
are shown. Bar =200 mm.
doi:10.1371/journal.pone.0016259.g007
Figure 8. Effect of S14G-HN on synaptic degeneration. A–D. Brain sections were subjected to immunostaining using anti-synaptophysin
antibody followed by visualization with avidin-fluorescein. Representative images of hippocampal CA3 region of vehicle (A, C) and S14G-HN (B, D)
treated mouse sections are shown. Bar =20 mm E. Synaptophysin fluorescence intensity in 25 mmX80 mm area of the hippocampal CA3 region was
measured. The relative value of S14G-HN-treated group (n=3) to vehicle group (n=3) is shown as mean6SD. P= indicates p value of t-test.
doi:10.1371/journal.pone.0016259.g008
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pathways/molecules involved in the Abeta-lowering effect.
Regarding AD-linked pathological features, previous studies
revealed that HN suppresses Abeta-induced neuronal death in vitro
and ameliorated amnesia caused by Abeta and muscarinic
receptor antagonists in vivo. In addition to these functions, this
study showed S14G-HN decreased Abeta burden in 3xTg-AD
mice, which is an additional in vivo function of HN as a
countermeasure against AD. We also showed that decreased
Abeta levels were associated with increased NEP levels in
hippocampal formation of 3xTg-AD mouse brains, suggesting
that HN is a NEP modulator.
Considering that intranasal administration is practically feasible
for clinical application, we chose intranasal treatment over
systemic methods in this study. Since the lack of significant
findings in some experiments, for instance memory retention in
Novel object recognition task (Fig. 2D), might be attributed to
suboptimal dosing, further studies will be necessary for pharma-
cological development. However, the present study contributes to
the preclinical evidence that intranasal administration of HN
represents a potential symptomatic and disease-modifying inter-
vention in AD. We note that the intranasal administration route
has been shown to provide effective delivery of peptides to the
central nervous system in humans. Further, a recent preliminary
study demonstrated cognitive benefits with intranasal administra-
tion of another peptide, AL-108 [75]. Additional preclinical
mechanistic and toxicological studies of HN are thus warranted,
and could lead to clinical studies of this peptide in AD.
Figure 9. Effect of S14G-HN on activation of signaling molecules. A, C, E. Immunoblot analysis of phosphorylation of STAT3 (A) and Akt
(C,E). Brain homogenate of 3xTg-AD mice treated with S14G-HN (H or HNG) or vehicle (V or veh) was subjected to immunoblot analysis to detect
phosphorylated proteins (upper panels) and total proteins (lower panels). B, D, F. Quantitative analysis of immunoblots. Intensity of bands
represented in A, C, E were measured (number of animals; vehicle male=7, female=9, S14G-HN male=9, female=7) and the ratio of phosphorylated
proten/total protein are shown as mean6SD. P= indicates p value of t-test. G–J. Brain sections were subjected to immunostaining using anti-
phospho-Tyr705 STAT3 and anti-rabbit-DyLight488 antibodies. Representative images of hippocampal region of vehicle (G, I) and S14G-HN (H, J)
treated mouse sections are shown. Bar =200 mm. L. Quantitative analysis of immunohistochemistry. The fluorescence intensity of phosphorylated
STAT3 in 75 mmX200 mm area of the hippocampal CA3 region was measured. The relative value of S14G-HN-treated group (n=3) to vehicle group
(n=3) is shown as mean6SD. P= indicates p value of t-test.
doi:10.1371/journal.pone.0016259.g009
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